![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
AVTE Aerovate
- 2.530
- 0.0000.00%
Close Dec 20 16:00 ET
- 2.530
- 0.0000.00%
Post 20:01 ET
73.14MMarket Cap-0.85P/E (TTM)
2.640High2.450Low768.55KVolume2.530Open2.530Pre Close1.94MTurnover6.46%Turnover RatioLossP/E (Static)28.91MShares32.41552wk High0.91P/B30.08MFloat Cap1.25052wk Low--Dividend TTM11.89MShs Float32.415Historical High--Div YieldTTM7.51%Amplitude1.250Historical Low2.526Avg Price1Lot Size
Aerovate Stock Forum
Sign in to post a comment
$Aerovate (AVTE.US)$ thanks in 2,40 out 2,89
2
4
$Aerovate (AVTE.US)$ good volume kick in
$Aerovate (AVTE.US)$ seems not good to me
$Aerovate (AVTE.US)$ not moving yet
1
$Aerovate (AVTE.US)$ Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
$Aerovate (AVTE.US)$
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
1
No comment yet
103892611 : yes
WeiTheSaint469 OP : thank God I got out lol